. 2022 Jun 7;29(9):2744–2753. doi: 10.1111/ene.15412

TABLE 5.

Change from baseline in total number of symptoms at Week 4 in non‐responders (<20% or <30% improvement in multiple sclerosis (MS) spasticity 0–10 numeric rating scale [NRS] score) and responders (≥20% or ≥30% improvement in MS spasticity 0–10 NRS score)

	<20% NRS improvement (n = 264)	≥20% NRS improvement (n = 874)	<30% NRS improvement (n = 727)	≥30% NRS improvement (n = 411)
	Mean (95% CI)
Baseline	0.71 (0.59–0.83)	1.65 (1.54–1.75)	1.18 (1.08–1.28)	1.86 (1.70–2.03)
4 weeks	0.48 (0.38–0.57)	1.10 (1.02–1.18) ^a	0.81 (0.74–0.88) ^b	1.21 (1.09–1.33)
Change from baseline	−0.23 (−0.30 to −0.17)	−0.54 (−0.60 to −0.48) ^a	−0.37 (−0.42 to −0.31) ^b	−0.65 (−0.75 to −0.56)
p value	0.1997		0.7128

Data were analyzed using analysis of covariance with responder rate (≥20% or ≥30% NRS improvement) as a factor and baseline number of symptoms as a covariate.

Abbreviations: CI, confidence interval, NRS, numeric rating scale.

^{^a}

n = 873.

^{^b}

n = 726.